FollowAnalysts at Maxim Group have initiated coverage of Momenta Pharmaceuticals, Inc. (MNTA) with a buy rating.
The firm set its price target on the stock at $24 a share, which is more than double its current market price.
Shares of MNTA are up 1% to $10.42 in the pre-market session, amid a 52-week trading range of $9.85 – $19.90.
The following two tabs change content below.
Kevin is a content-crafter at Wallstreet OTC specializing in editorial and news. He promised us that he will keep his articles short but he always seem to stop only when the character count maximum.
